Cemex (NYSE:CX) reported quarterly sales of $4.08 billion which beat the analyst consensus estimate of $3.73 billion by 9.38 percent. This is a 5.84 percent increase over sales of $3.85 billion the same period last year.
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application For Phase 2 Study Of Oral TNF-α Inhibitor MYMD-1 In Rheumatoid Arthritis
- Next-generation and first oral TNF-α inhibitor, which completed Phase 2 study for age-related condition sarcopenia, represents a potentially groundbreaking advance in the treatment of RA and disruption of
